Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

KRAS mutations are one of the most common oncogenic drivers in non-small cell lung cancer (NSCLC) and in lung adenocarcinomas in particular. Development of therapeutics targeting KRAS has been incredibly challenging, prompting indirect inhibition of downstream targets such as MEK and ERK. Such inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldelli, Elisa, El Gazzah, Emna, Moran, John Conor, Hodge, Kimberley A., Manojlovic, Zarko, Bassiouni, Rania, Carpten, John D., Ludovini, Vienna, Baglivo, Sara, Crinò, Lucio, Bianconi, Fortunato, Dong, Ting, Loffredo, Jeremy, Petricoin, Emanuel F., Pierobon, Mariaelena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467269/
https://www.ncbi.nlm.nih.gov/pubmed/34573384
http://dx.doi.org/10.3390/genes12091402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467269/
https://www.ncbi.nlm.nih.gov/pubmed/34573384
http://dx.doi.org/10.3390/genes12091402

Ejemplares similares